NCT07365319Phase 2, phase 3Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2035-12-31Estimated

Enrollment · participants750Estimated

Source updated2026-09-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-20 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Non Small Cell Lung Cancer (Squamous or Non Squamous); Stage 4 NSCLC

Treatments or interventions studied

EIK1001Drug
Pembrolizumab (KEYTRUDA®)Drug
PlaceboDrug
Paclitaxel + CarboplatinDrug
Nab-paclitaxel + CarboplatinDrug
Pemetrexed + Cisplatin /CarboplatinDrug

Primary outcomes · main study measures

Read the study measures

measure: Progression-free survival (PFS); description: Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by BICR, or death due to any cause, whichever occurs first; timeFrame: Through study completion, up to 6 years; measure: Overall survival (OS); description: OS defined as the time from the first dose of study medication to death due to any cause; timeFrame: Through study completion, up to 10 years; measure: Objective Response (OR); description: Objective response (OR) is defined as participants who demonstrate complete response (CR) or partial response (PR) by RECIST 1.1 as assessed by the Investigator, adverse events (AEs), and discontinuation of study intervention due to an AE (Dose Optimization Only).; timeFrame: Through study completion, up to 6 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history